Kairos Pharma (NYSEAMERICAN:KAPA) Shares Down 2.2% – Here’s Why

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) traded down 2.2% on Wednesday . The company traded as low as $0.8260 and last traded at $0.84. 82,735 shares were traded during trading, a decline of 43% from the average session volume of 144,729 shares. The stock had previously closed at $0.8592.

Wall Street Analysts Forecast Growth

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Kairos Pharma in a report on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Kairos Pharma has a consensus rating of “Buy” and an average target price of $8.33.

Kairos Pharma Trading Down 2.2%

The firm has a 50-day moving average price of $0.98 and a 200-day moving average price of $0.98. The company has a market capitalization of $17.49 million, a price-to-earnings ratio of -2.71 and a beta of 2.20.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its earnings results on Friday, November 14th. The company reported ($0.07) earnings per share for the quarter.

Institutional Trading of Kairos Pharma

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Two Sigma Investments LP acquired a new stake in Kairos Pharma during the third quarter valued at approximately $54,000. XTX Topco Ltd acquired a new position in Kairos Pharma in the second quarter worth approximately $44,000. Finally, Armistice Capital LLC bought a new position in shares of Kairos Pharma in the first quarter valued at $1,314,000.

About Kairos Pharma

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.